Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 8/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16238305 | 0.89 | — | — | |
| SCHEMBL28204907 | 0.84 | TP53 (0.50) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL9254730 | 0.84 | TP53 (0.50) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL1077444 | 0.84 | TP53 (0.50) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL2712401 | 0.81 | TP53 (0.46) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL14141274 | 0.78 | — | — | |
| SCHEMBL15352983 | 0.77 | TSHR (0.45) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL23898420 | 0.76 | CPN1 (0.34) | PMP22DPP4 | |
| Benzene SCHEMBL27966857 | 0.76 | TP53 (0.44) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL9545134 | 0.75 | TP53 (0.44) | TP53KDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160102058-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160102058-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160102058-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2016-04-14 | — | — | US | disclosed |
| EP-2997012-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | The University Court of The University of Aberdeen (GB) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014184561-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184561-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102058-A1 | FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE | CPT2, CPT1A, CPT1B | TP53 1202/4885KDM4E 1718/4885GMNN 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.